Myriad Genetics, Inc. (MYGN) Tops Q1 EPS by 1c, Reaffirms FY12 Guidance
Tweet
Share
E-mailGet Alerts MYGN Hot Sheet
Price: $5.88 +8.29%
Revenue Growth %: -2.7%
Financial Fact:
Molecular diagnostic testing: 165.1M
Today's EPS Names:
CGEH, NAKA, APOG, More
Revenue Growth %: -2.7%
Financial Fact:
Molecular diagnostic testing: 165.1M
Today's EPS Names:
CGEH, NAKA, APOG, More
Join SI Premium – FREE
Myriad Genetics, Inc. (NASDAQ: MYGN) reported Q1 EPS of $0.29, $0.01 better than the analyst estimate of $0.28. Revenue for the quarter came in at $110.5 million versus the consensus estimate of $106.49 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Myriad Genetics expands Precise MRD cancer test to three tumor types
- Yiren Digital Ltd. (YRD) Reports Q1 Loss of RMB5.64
- FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
